Pulse Biosciences Inc

In a Stage 2 advancing uptrend, medium-term bias remains bullish despite a recent bullish exhaustion signal, and price is currently pulling back into rising EMAs on neutral indicators, offering a tactical pullback entry. Execution now at the 9/21 EMA support zone aligns with trend structure, while caution is warranted for a potential distribution if price breaks below the EMAs.

• ↑Q4 2025 revenue $264K, up from $86K in Q3 2025, showing early NSPFA traction.
• ↑NSPFA delivered 96% procedural success in atrial fibrillation ablations.
• ↓GAAP net loss widened to $19.2M in Q3 2025 vs $12.7M year-ago, raising sustainability concerns.